News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Speedel Holding AG Release: Expansion Of ASPIRE HIGHER Clinical Trial Programme For Spp100 (Rasilez/Tekturna)



6/17/2008 12:00:10 PM

BASEL, SWITZERLAND--(Marketwire - June 17, 2008) - Speedel Holding Ltd. (SWX: SPPN) highlighted today that Novartis is to expand the clinical trial programme with SPP100 (aliskiren; Rasilez/Tekturna[1]) to study organ protection potential beyond the already shown powerful reduction of blood pressure. Novartis announced details of two new long-term outcome studies in its landmark ASPIRE HIGHER clinical trial programme. This series of trials now form the largest and most far-reaching cardio-renal outcomes programme worldwide.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES